Study of HS-20105 for Injection in Patients With Advanced Solid Tumors.
Status:
Not yet recruiting
Trial end date:
2027-03-01
Target enrollment:
Participant gender:
Summary
HS-20105 is a novel antibody-drug conjugate (ADC) targeting Trop-2. This first-in-human trial
is aimed to assess the maximum tolerated dose (MTD) and dose limiting toxicity (DLT), to
evaluate the pharmacokinetics (PK), safety and preliminary anti-tumor activity of HS-20105 in
patients with advanced solid tumors.